株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の抗真菌剤市場調査と予測

Global Antifungal Agents Market Research and Forecast, 2018-2023

発行 Orion Market Research Pvt Ltd 商品コード 762916
出版日 ページ情報 英文
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
世界の抗真菌剤市場調査と予測 Global Antifungal Agents Market Research and Forecast, 2018-2023
出版日: 2018年12月05日 ページ情報: 英文
概要

当レポートでは、世界の抗真菌剤市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 調査サマリー

第3章 市場概要と考察

  • 市場の定義
  • バリューチェーン分析
  • アナリストの見解と現在の市場動向
  • 規則と規制

第3章 市場決定因子

  • 促進因子
  • 阻害因子
  • 機会

第4章 市場セグメンテーション

  • 薬剤クラス別市場
    • ポリエン
    • エキノキャンディン
    • アリルアミン
    • アゾール
  • 剤形別市場
    • 粉末
    • 軟膏
    • 薬剤
    • ペースト
  • 投与ルート別市場
    • 非経口
    • 局所
    • 経口

第5章 競合環境

  • 主な戦略分析
  • 主要企業分析

第6章 地域別分析

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第7章 企業のプロファイル

図表

List of Tables

  • TABLE # 1 GLOBAL ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2017-2023 ($ MILLION)
  • TABLE # 2 GLOBAL POLYENE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 3 GLOBAL ECHINOCANDINS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 4 GLOBAL ALLYLAMINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 5 GLOBAL AZOLE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 6 GLOBAL ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2017-2023 ($ MILLION)
  • TABLE # 7 GLOBAL POWDERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 8 GLOBAL OINTMENTS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 9 GLOBAL DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 10 GLOBAL PASTES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 11 GLOBAL ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2017-2023 ($ MILLION)
  • TABLE # 12 GLOBAL PARENTERAL MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 13 GLOBAL TOPICAL MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 14 GLOBAL ORAL MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 15 GLOBAL ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
  • TABLE # 16 NORTH AMERICAN ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 17 NORTH AMERICAN ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY DRUG-CLASS, 2017-2023 ($ MILLION)
  • TABLE # 18 NORTH AMERICAN ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2017-2023 ($ MILLION)
  • TABLE # 19 NORTH AMERICAN ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2017-2023 ($ MILLION)
  • TABLE # 20 EUROPEAN ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 21 EUROPEAN ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY DRUG-CLASS, 2017-2023 ($ MILLION)
  • TABLE # 22 EUROPEAN ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2017-2023 ($ MILLION)
  • TABLE # 23 EUROPEAN ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2017-2023 ($ MILLION)
  • TABLE # 24 APAC ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 25 APAC ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY DRUG-CLASS, 2017-2023 ($ MILLION)
  • TABLE # 26 APAC ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2017-2023 ($ MILLION)
  • TABLE # 27 APAC ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2017-2023 ($ MILLION)
  • TABLE # 28 ROW ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2017-2023 ($ MILLION)
  • TABLE # 29 ROW ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2017-2023 ($ MILLION)
  • TABLE # 30 ROW ANTIFUNGAL AGENTS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL ANTIFUNGAL AGENTS MARKET SHARE BY DRUG-CLASS, 2017 VS 2023 (%)
  • FIGURE # 2 GLOBAL ANTIFUNGAL AGENTS MARKET SHARE BY DOSAGE TYPE, 2017 VS 2023 (%)
  • FIGURE # 3 GLOBAL ANTIFUNGAL AGENTS MARKET SHARE BY ROUTE OF ADMINISTRATION, 2017 VS 2023 (%)
  • FIGURE # 4 US ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 5 CANADA ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 6 UK ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 7 FRANCE ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 8 GERMANY ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 9 ITALY ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 10 SPAIN ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 11 ROE ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 12 INDIA ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 13 CHINA ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 14 SOUTH KOREA ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 15 JAPAN ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 16 ROAPAC ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 17 REST OF THE WORLD ANTIFUNGAL AGENTS MARKET SIZE, 2017-2023 ($ MILLION)
目次
Product Code: OMR2018440

Global antifungal agents market is expected to grow at a moderate rate during the forecast period. This market includes drugs, powder, ointments, and pastes that are used to treat fungal infections. These antifungal agents prevent and destroy the growth of fungi that are responsible for various diseases such as aspergillosis, ringworm, skin infection and so forth. The antifungal drugs include azoles, polyenes, Echinocandins and allylamines. These drugs are widely used for the treatment of several fungal infections such as candidiasis, ringworm and tinea pedis. Increasing funding programs for the development of antifungal agents support in the effective treatment of fungal diseases. For instance, in June 2016, the Department of Molecular Genetics & Microbiology, Stony Brook University received a grant valued over $6.0 million from the National Institute of Health (NIH). This grant was intended to discover new approaches for the treatment of fungal infections based on collaborative and laboratory research along with experts, globally. They will collaborate for the development of the new class of antifungal agents. According to the experts, systemic fungal infections cause over one million fatalities each year. In addition, the treatment of such conditions is generally not effective coupled with drug resistance or toxicity. Thus, the funding from NIH enables recognizing the widespread requirement for potential antifungal treatments. As a result, it enables to drive the growth of the global antifungal agents market.

Moreover, other factors that are contributing towards the growth of antifungal agents market include rising incidence and prevalence of fungal diseases, advances in antifungal agents and increasing demand for azole class of drugs. However, adverse effects associated with antifungal drugs and stringent government regulations are creating hurdles in the market growth. The market is offering significant growth opportunities due to improving healthcare infrastructure and growing awareness about fungal infections. The global antifungal agents market has been segmented on the basis of application, drug-class, type and route of administration. According to drug-class, the market is further classified into polyenes, echinocandins, allylamines, azoles and others (flucytosine, griseofulvin and tolnaftate). Azoles class of drugs is gaining a significant position as it is one of the most preferred options for the treatment of systemic fungal infections. Based on the type, the market is classified into powders, ointments, drugs and pastes. According to the route of administration, the market is further classified into parenteral, topical and oral. Topical antifungals are considered as an essential adjuvant to treat dermatophytosis. Moreover, in certain conditions, including dermatophytosis in infants and pregnancy usually warrant topic therapy. This enables to drive the demand for topical antifungals.

Furthermore, the market is classified on the basis of geography, such as North America, Europe, and Asia Pacific & RoW. North America is expected to witness significant share in the global antifungal agents market due to increasing prevalence of fungal infections in the region. However, APAC is expected to hold a remarkable position in near future due to improving healthcare infrastructure and prevalence of invasive fungal infections in the countries, including China and India.

Some of the major players contributing into the growth of antifungal agents include Abbott Laboratories, Inc., Bayer Healthcare AG, Gilead Sciences, Inc., and Pfizer, Inc. These companies used various strategies such as mergers & acquisition, product launch, collaborations to remain in the competition. For instance, In June 2017, Pfizer Inc. and Basilea Pharmaceutica AG, a Switzerland-based firm specialized in the R&D of oncological and anti-infective medicine has signed a collaboration agreement for commercialization rights of CRESEMBA in Europe. Under the terms of the agreement, Pfizer will be allowed to commercialize CRESEMBA (isavuconazole), a new antifungal treatment aimed for adult patients with invasive mucormycosis and aspergillosis in Europe. According to Pfizer, Inc. with this collaboration, the company will further optimize the value of CRESEMBA in essential regions of the world.

Research methodology

The market study of global antifungal agents market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include

  • Financial reports of companies involved in the market
  • Authentic Public Databases such as cdc.gov, ncbi.nlm.nih.gov and so on.
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalogue

The report is intended for government and private companies for overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers and initial norms. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market segmentation

1. Global Antifungal Agents Market Research and Analysis, By Drug-class

2. Global Antifungal Agents Market Research and Analysis, By Dosage Type

3. Global Antifungal Agents Market Research and Analysis, By Route of Administration

4. Global Antifungal Agents Market Research and Analysis, By Region

THE REPORT COVERS

  • Comprehensive research methodology of global antifungal agents market.
  • This report also includes detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global antifungal agents market.
  • Insights about market determinants which are stimulating the global antifungal agents market

Table of Contents

CHAPTER 1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

CHAPTER 2. Market Overview and Insights

  • 2.1. Market Definition
  • 2.2. Value Chain Analysis
  • 2.3. Analyst Insight & Current Market Trends
    • 2.3.1. Key Findings
    • 2.3.2. Recommendation
    • 2.3.3. Conclusion
  • 2.4. Rules & Regulations
    • 2.4.1. United States
    • 2.4.2. European Union
    • 2.4.3. China
    • 2.4.4. Japan
    • 2.4.5. India

CHAPTER 3. Market Determinant

  • 3.1. Motivators
    • 3.1.1. Rising Incidence and Prevalence of Fungal Diseases
    • 3.1.2. Growing R&D Funding and Investment
    • 3.1.3. Advances in Antifungal Agents
    • 3.1.4. Increasing Demand for Azole Antifungal Drugs
  • 3.2. Restraints
    • 3.2.1. Adverse Effects Associated with the Antifungal Drugs
    • 3.2.2. Stringent Government Regulations
  • 3.3. Opportunities
    • 3.3.1. Improving Healthcare Infrastructure
    • 3.3.2. Rising Awareness About Fungal Infection

CHAPTER 4. Market Segmentation

  • 4.1. Global Antifungal Agents Market, By Drug Class
    • 4.1.1. Polyene
    • 4.1.2. Echinocandins
    • 4.1.3. Allylamines
    • 4.1.4. Azole
  • 4.2. Global Antifungal Agents Market, By dosage type
    • 4.2.1. Powders
    • 4.2.2. Ointments
    • 4.2.3. Drugs
    • 4.2.4. Paste
  • 4.3. Global Antifungal Agents Market, By Route of Administration
    • 4.3.1. Parenteral
    • 4.3.2. Topical
    • 4.3.3. Oral

CHAPTER 5. Competitive Landscape

  • 5.1. Key Company Analysis
  • 5.2. Key Strategy Analysis

CHAPTER 6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. U.K
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Roe
  • 6.3. Asia Pacific
    • 6.3.1. India
    • 6.3.2. China
    • 6.3.3. South Korea
    • 6.3.4. Japan
    • 6.3.5. RoAPAC
  • 6.4. Rest of the World

CHAPTER 7. Company Profiles

  • 7.1. Abbott Laboratories, Inc.
  • 7.2. Amplyx Pharmaceuticals, Inc.
  • 7.3. Astellas Pharma, Inc.
  • 7.4. Basilea Pharmaceutica AG
  • 7.5. Bayer Healthcare LLC
  • 7.6. Bristol-Myers Squibb Pharmaceuticals, Ltd.
  • 7.7. Cosmo Pharmaceuticals NV
  • 7.8. Gilead Sciences, Inc.
  • 7.9. Janssen Pharmaceutica NV
  • 7.10. Mayne Pharma, Inc.
  • 7.11. Merck & Co., Inc.
  • 7.12. Mylan Pharmaceuticals, Inc.
  • 7.13. Nouvasant Pharmhealth Ltd.
  • 7.14. Pfizer, Inc.
  • 7.15. Sanofi-Aventis U.S. LLC
  • 7.16. Scynexis, Inc.
  • 7.17. Sumitomo Dainippon Pharma Co., Ltd.
  • 7.18. Sun Pharmaceutical Industries, Ltd.
  • 7.19. Teva Pharmaceutical Industries, Ltd.
  • 7.20. Zydus Cadila Healthcare Ltd.
Back to Top